Biogen and Alkermes Report Results of Diroximel Fumarate in P-III EVOLVE-MS-2 Study for Multiple Sclerosis

Biogen and Alkermes Report Results of Diroximel Fumarate in P-III EVOLVE-MS-2 Study for Multiple Sclerosis

Shots:

  • The P-III EVOLVE-MS-2 study assessing the GI tolerability of Diroximel Fumarate (462mg, bid) vs Tecfidera (dimethyl fumarate, 240 mg, bid) in 506 patients with RRMS
  • The P-III EVOLVE-MS-2 study results demonstrated superiority in gastrointestinal (GI) tolerability with a symptom intensity score ≥2 on the IGISIS rating scale and low discontinuation rates of <1% due to GI adverse events
  • Diroximel fumarate is a fumarate therapy designed to convert to monomethyl fumarate in the body and is under the US FDA review with its expected PDUFA date in Q4’19. Post-FDA’s approval, Biogen plans to market diroximel fumarate under the name Vumerity

Click here to­ read full press release/ article | Ref: Biogen | Image: Shigotoba